Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerance of Immunomodulating Therapy With Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation, a 24-month, Non-randomized, Open-label, Prospective, Single-center Pilot Trial

NCT02957552 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT02957552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02957552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerance of Immunomodulating Therapy With Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation, a 24-month, Non-randomized, Open-label, Prospective, Single-center Pilot Trial
Lead sponsor
University Hospital Tuebingen
Phase
Phase 1
Overall status
Unknown status
Start date
March 10, 2017
Completion date
December 31, 2021
Enrollment
7 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric liver transplantation